7.4.4.2.1  Summary of evidence and recommendation for targeted therapy in non-clear-cell metastatic RCC,
Summary of evidence,LE
Both mTOR inhibitors and VEGF-targeted therapies have limited activity in non-cc-mRCC. There   is a non-significant trend for improved oncological outcomes for sunitinib over everolimus and for   cabozantinib over sunitinib.,2a
"In non-cc-mRCC, sunitinib improved PFS over everolimus in a systematic review of phase II trials and   subgroups of patients.",1a
